US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Kiromic BioPharma, Inc. - Common Stock (NQ:KRBP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.6931 (95)
Ask (Size) 0.7000 (3)
Prev. Close 1.450
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 1,288,235
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
From Kiromic BioPharma, Inc.
Via Business Wire

Performance

More News

Read More
News headline image
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024 ↗
Via InvestorPlace
News headline image
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma Announces Uplisting to OTCQB Market
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
From Kiromic BioPharma
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Via Benzinga
News headline image
Kiromic BioPharma Welcomes Two New Directors to its Board
From Kiromic BioPharma, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Via Benzinga
News headline image
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Kiromic BioPharma, Inc. - Common Stock publicly traded?
Yes, Kiromic BioPharma, Inc. - Common Stock is publicly traded.
What exchange does Kiromic BioPharma, Inc. - Common Stock trade on?
Kiromic BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kiromic BioPharma, Inc. - Common Stock?
The ticker symbol for Kiromic BioPharma, Inc. - Common Stock is KRBP on the Nasdaq Stock Market